selegiline has been researched along with Nervous System Disorders in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Buchwalder, C; Devineau, A; Dullaghan, EM; Gealageas, R; Goebeler, V; Grierson, DS; Heller, M; Kim, CMJ; Putnins, EE; So, PPL; Surendradoss, J | 1 |
| Ishibashi, K; Ishii, K; Kameyama, M; Miura, Y; Toyohara, J | 1 |
| Schneemilch, C | 1 |
| Fann, JR | 1 |
| Miklya, I; Shimazu, S | 1 |
| Brown-Borg, H; Carlson, EC; Ebadi, M; El ReFaey, H; Ren, J; Sharma, S; Shavali, S | 1 |
| Gerlach, M; Riederer, P; Youdim, MB | 1 |
| Berry, MD; Juorio, AV; Paterson, IA | 1 |
| Agnati, LF; Biagini, G; Frasoldati, A; Fuxe, K | 1 |
| Benmansour, S; Brunswick, DJ | 1 |
| Agata, M; Matsumoto, J; Sasada, N; Takahashi, T; Toyofuku, H | 1 |
| Kuhn, W; Müller, T | 1 |
| Knoll, J | 1 |
| Wagner, GC; Walsh, SL | 1 |
| DeLanney, LE; Finnegan, KT; Irwin, I; Langston, JW; Skratt, JJ | 1 |
| Fuller, RW; Hemrick-Luecke, SK | 1 |
7 review(s) available for selegiline and Nervous System Disorders
| Article | Year |
|---|---|
Neurological effects of psychopharmacological agents.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents; Bundle-Branch Block; Delirium; Depressive Disorder; Humans; Lithium; Male; Nervous System Diseases; Parkinson Disease; Psychotropic Drugs; Selegiline | 2002 |
Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Topics: Animals; Antidepressive Agents; Benzofurans; Humans; Mesencephalon; Nervous System Diseases; Neuroprotective Agents; Phenethylamines; Psychotropic Drugs; Selegiline; Tryptamines | 2004 |
Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases.
Topics: Animals; Humans; Nervous System Diseases; Neurodegenerative Diseases; Selegiline | 2006 |
Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.
Topics: Animals; Humans; Nervous System Diseases; Parkinson Disease; Selegiline; Vitamin E | 1995 |
Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Depressive Disorder; Humans; Longevity; Mental Disorders; Monoamine Oxidase Inhibitors; Nervous System Diseases; Parkinson Disease; Schizophrenia; Selegiline | 1994 |
The clinical potential of Deprenyl in neurologic and psychiatric disorders.
Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome | 1996 |
Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases.
Topics: Aging; Animals; Drug Administration Schedule; Humans; Nervous System Diseases; Selegiline; Structure-Activity Relationship | 1992 |
9 other study(ies) available for selegiline and Nervous System Disorders
| Article | Year |
|---|---|
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Dogs; Drug Development; Humans; Madin Darby Canine Kidney Cells; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nervous System Diseases | 2018 |
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Topics: Aminopyridines; Carbon Radioisotopes; Female; Gliosis; Humans; Ligands; Male; Monoamine Oxidase; Nervous System Diseases; Positron-Emission Tomography; Quinolines; Selegiline | 2021 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |
The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes.
Topics: Animals; Astrocytes; Cell Division; Densitometry; Fibroblast Growth Factor 2; Glial Fibrillary Acidic Protein; Image Processing, Computer-Assisted; Immunohistochemistry; Male; Neostriatum; Nerve Degeneration; Nervous System Diseases; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine.
Topics: Animals; Autoradiography; Body Temperature; Brain; Clorgyline; Drug Synergism; Iodocyanopindolol; Male; Nerve Endings; Nervous System Diseases; Neurons; p-Chloroamphetamine; Pargyline; Pindolol; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selegiline; Serotonin | 1994 |
A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Monoamines; Brain; Dopamine; In Vitro Techniques; Liver; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondria, Liver; Monoamine Oxidase; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neostriatum; Nervous System Diseases; Oxadiazoles; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage.
Topics: Aging; Animals; Clorgyline; Corpus Striatum; Dopamine; Male; Methamphetamine; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nervous System Diseases; Neurons; Selegiline | 1991 |
Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.
Topics: Allyl Compounds; Animals; Benzylamines; Butylamines; Hippocampus; Kinetics; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Nervous System Diseases; Norepinephrine; Selegiline | 1990 |
A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; Mice, Inbred Strains; Nervous System Diseases; Phenethylamines; Pyridines; Receptors, Dopamine; Selegiline | 1989 |